Canaccord lowered the firm’s price target on Waldencast (WALD) to $2 from $4 and keeps a Buy rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on WALD:
- Waldencast Posts Flat 2025 Results as Obagi Surges, Launches Strategic Review and Deleveraging Drive
- Waldencast reports Q4 revenue $72M vs. $72.1M last year
- Obagi Medical, Schweiger Dermatology collaborate for ALOHA program
- Obagi Medical, It’s a Secret Med Spa collaborate for ALOHA program
- Obagi Medical, Aesthetic Record collaborate for ALOHA program